نتائج البحث

| group1 = [[5-HT3 antagonist|5-HT3 Serotonin ion channel antagonist]]s | group2 = [[Serotonin antagonist|5-HT Serotonin G-protien receptor antagonist]]s

| group2 = [[Cannabinoid receptor antagonist|Cannabinoid<br />receptor antagonists]]

* ''[[Cannabinoid receptor type 1|CB1]]'' ([[Surinabant]]) * ''[[Metabotropic glutamate receptor|mGluR]]'' ([[Acamprosate]])

*[[5-HT3 antagonist|5-HT₃ receptor antagonists]] – these block [[serotonin]] receptors in the [[central nerv *[[Dopamine antagonist]]s act in the brain and are used to treat nausea and vomiting associated wi

|group1= [[Psychedelic drug|Psychedelics]]<br />''<small>[[5-HT2A receptor|5-HT_2AR]] [[Serotonergic psychedelic|agonists]]</small>'' | group2 = [[Dissociative]]s<br />''<small>[[NMDA receptor|NMDAR]] [[NMDA antagonist|antagonists]]</small>''

...act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.] Neuropharmacology. 2012 Oct;63(5):905-15. doi: 10.101 ...ref>JAMA. 2006 Feb 15;295(7):761-75. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese